Please join us via Zoom or use this streaming link (coming soon). Presentations qualify for CME credit. To obtain your CME credit, you will need to use the Cloud CME system.
Monitoring the Wild West of Psychedelics Proliferation
Andrew Monte, MD, PhD
Professor of Emergency Medicine & Medical Toxicology; Associate Director Rocky Mountain Poison & Drug Center
Dale Terasaki, MD, MPH
Assistant Professor of Colorado Division of General Internal Medicine
Learning Objectives
- Distinguish between the approach of Colorado's Natural Medicine Program and cannabis legalization.
- List 2 different methods of obtaining surveillance data of psychedelics.
- Describe 2 national trends in use of psychedelics.
Persons with a disability may request a reasonable accommodation, such as a sign language interpreter, by contacting us at 520-874-4082. Requests should be made as early as possible to allow time to arrange the accommodation.
Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Arizona College of Medicine - Tucson and Southern Arizona Veterans Affairs Health Care System The University of Arizona College of Medicine - Tucson is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Arizona College of Medicine - Tucson designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Relevant Financial Relationships Statement(s):
University of Arizona College of Medicine - Tucson Office of Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). The CME office reviewers have nothing to disclose. All relevant financial relationships have been mitigated prior to the commencement of the activity.
| Name | Individual's role in activity | Nature of relationship(s) / Name of inelegible company(s) |
|---|---|---|
| Elisa Gumm, DO | Activity Director | Nothing to disclose - 06/10/2024 |
| Andrew Monte, MD, PhD | Presenter | Coming soon |
| Dale Terasaki, MD, MPH | Presenter | Coming Soon |